Repeated adolescent MDMA ("Ecstasy") exposure in rats increases behavioral and neuroendocrine responses to a 5-HT2A/2C agonist

Brain Research

Volumn 1252, Issue , 2009, Pages 87-93

  Biezonski, Dominik K ^a   Courtemanche, Andrea B ^a   Hong, Sang B ^b   Piper, Brian J ^a   Meyer, Jerrold S ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

^b AMHERST COLLEGE   (United States)

Author keywords

5 HT2A; Adolescence; Behavior; MDMA; Neuroendocrine; Rats

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; CORTICOSTERONE; KETANSERIN; KETANSERIN H 3; PROLACTIN; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C AGONIST; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACK MUSCLE; DNA FLANKING REGION; FOREBRAIN; HEAD TWITCH; HYPOTHALAMUS; MUSCLE CONTRACTION; NEUROENDOCRINE SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

AMPHETAMINES; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CORTICOSTERONE; KETANSERIN; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROSECRETORY SYSTEMS; PROLACTIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGENTS;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 58349107071     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.11.045     Document Type: Article

References (46)

1. Aghajanian G.K., and Marek G.J. Serotonin and hallucinogens. Neuropsychopharmacology 21 2 Suppl. (1999) 16S-23S
2. 2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses. Behav Brain Res. 73 (1996) 277-280
3. 2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr. Top. Med. Chem. 6 (2006) 1971-1985
4. 2A receptor responsivity. Neuropharmacology 46 (2004) 202-210
5. 2A receptor-mediated glucose utilization in the rat brain. J. Psychopharmacol. 20 (2006) 272-280
6. Burns N., Olverman H.J., Kelly P.A., and Williams B.C. Effects of ecstasy on aldosterone secretion in the rat in vivo and in vitro. Endocr. Res. 22 (1996) 601-606
7. 11 proteins in rats undergoing withdrawal. J. Pharmacol. Exp. Ther. 311 (2004) 349-355
8. Carrasco G.A., and Van de Kar L.D. Neuroendocrine pharmacology of stress. Eur. J. Pharmacol. 463 (2003) 235-272
9. 2A receptors in depression. J. Psychiatry Neurosci. 29 (2004) 252-265
10. 2A receptor-mediated head shakes, and behaviours in models of anxiety. Neuropharmacology. 33 (1994) 449-456
11. Chen Z., Waimey K., Van de Kar L.D., Carrasco G.A., Landry M., and Battaglia G. Prenatal cocaine exposure potentiates paroxetine-induced desensitization of 5-HT2A receptor function in adult male rat offspring. Neuropharmacology 46 (2004) 942-953
12. 2A receptor and the pathology of schizophrenia: a likely accomplice. J. Neurochem. 85 (2003) 1-13
13. Du L., Faludi G., Palkovits M., Bakish D., and Hrdina P.D. Serotonergic genes and suicidality. Crisis 22 (2001) 54-60
14. Emiliano A.B., and Fudge J.L. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 29 (2004) 833-846
15. European Monitoring Center for Drugs and Drug Addiction, 2005. Lifetime prevalence of psychoactive substance use among 15- to 16-year-old students. Accessed 7/2008 at: http://stats04.emcdda.eu.int/index.cfm?fuseaction=public.Content&nNodeID=5388.
16. Fantegrossi W.E., Ullrich T., Rice K.C., Woods J.H., and Winger G. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology 161 (2002) 356-364
17. Fone K.C., Beckett S.R., Topham I.A., Swettenham J., Ball M., and Maddocks L. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology 159 (2002) 437-444
18. Fone K.C., Robinson A.J., and Marsden C.A. Characterization of the 5-HT receptor subtypes involved in the motor behaviours produced by intrathecal administration of 5-HT agonists in rats. Br. J. Pharmacol. 103 (1991) 1547-1555
19. 2A,C receptor agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Neuropsychobiology 37 (1998) 36-40
20. Green A.R., Mechan A.O., Elliot J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55 (2003) 463-508
21. 2A receptor in learning. Learn. Mem. 10 (2003) 355-362
22. 2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology 178 (2005) 505-513
23. Hopfer C., Mendelson B., Van Leeuwen J.M., Kelly S., and Hooks K.S. Club drug use among youths in treatment for substance abuse. Am. J. Addict. 15 (2006) 94-99
24. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, 1996. Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
25. 2A receptor-mediated behavior in rats after a single footshock. Eur. J. Pharmacol. 452 (2002) 199-204
26. Johnson L.D., O'Malley P.M., Bachman J.G., and Schulenberg J.E. Monitoring the Future National Survey Results on Drug Use, 1975-2006: Volume I, Secondary School Students (2007), National Institute on Drug Abuse, Bethesda, MD (NIH Publication # 07-6205)
27. Kaye W.H., Frank G.K., Bailer U.F., Henry S.E., Meltzer C.C., Price J.C., Mathis C.A., and Wagner A. Serotonin alterations in anorexia and bulimia nervosa: new insights from imaging studies. Physiol. Behav. 85 (2005) 73-81
28. Kindludh-Högberg A.M., Svenningsson P., and Schiöth H.B. Quantitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain. Neuropharmacology 51 (2006) 838-847
29. Kitamura Y., Shibata K., Akiyama K., Kimoto S., Fujitani Y., Kitagawa K., Kanzaki H., Ouchida M., Shimizu K., Kawasaki H., Sendo T., and Gomita Y. Increased DOI-induced wet-dog shakes in adrenocorticotropic hormone-treated rats are not affected by chronic imipramine treatment: possible involvement of enhanced 5-HT(2A)-receptor expression in the frontal cortex. J. Pharmacol. Sci. 106 (2008) 100-106
30. 2 receptor binding sites: binding properties, brain distribution, and functional role. Mol. Pharmacol. 21 (1981) 301-314
31. Meyer J.S., Piper B.J., and Vancollie V.E. Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence. Ann. N. Y. Acad. Sci. 1139 (2008) 151-163
32. Piper B.J. A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). Neurotoxicol. Teratol. 29 (2007) 288-300
33. 1A receptor agonist. J. Pharmacol. Exp. Ther. 317 (2006) 838-849
34. 2A receptors in rat and human brain. Neuropsychopharmacology 26 (2002) 387-396
35. Samson W.K., Taylor M.M., and Baker J.R. Prolactin-releasing peptides. Regul. Pept. 1 (2003) 1-5
36. Sodhi M.S.K., and Sanders-Bush E. Serotonin in brain development. Int. Rev. Neurobiol. 59 (2004) 111-174
37. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 4 (2000) 417-463
38. Spear L.P. Assessment of adolescent neurotoxicity: rationale and methodological considerations. Neurotoxicol. Teratol. 1 (2007) 1-9
39. Torner L., Toschi N., Pohlinger A., Landgraf R., and Neumann I.D. Anxiolytic and anti-stress effects of brain prolactin: improved efficacy of antisense targeting of the prolactin receptor by molecular modeling. J. Neurosci. 21 (2001) 3207-3214
40. United Nations Office of Drug Control & Crime 2007: 2007 World Drug Report, ISBN: 978-92-1-148222-5.
41. 2A receptors using antisense oligonucleotides, J. Neurochem. 85 (2003) 1087-1100
42. 2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J. Neurosci. 21 (2001) 3572-3579
43. Van de Kar L.D., Rittenhouse P.A., Li Q., and Levy A.D. Serotonergic regulation of renin and prolactin secretion. Behav. Brain Res. 73 (1996) 203-208
44. Van Wijngaarden I., Tulp M.T., and Soudijn W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. 188 (1990) 301-312
45. 2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J. Pharmacol. Exp. Ther. 282 (1997) 699-706
46. 2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI. J. Neurosci. 22 (2002) 9635-9642